Founded
2022
Stage
Series A
Team size
1-10 employees
Sector
Health & Life Sciences
About
AI-driven precision oncology company spun out of argenx and the University of Colorado Anschutz Medical Campus, advancing cusatuzumab for newly diagnosed AML. Raised a $30M Series A in 2023 and a Series A extension in November 2024 (about $44M total) to fund its Phase 2 trial.
Funding
Last roundSeries A Extension
Funding detail is compiled from public sources and may lag recent activity.